Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China by Yali Hu et al.
RESEARCH ARTICLE Open Access
Gaps in the prevention of perinatal transmission
of hepatitis B virus between recommendations
and routine practices in a highly endemic region:
a provincial population-based study in China
Yali Hu1,4†, Shu Zhang1†, Chao Luo1, Qilan Liu2 and Yi-Hua Zhou3,4*
Abstract
Background: Hepatitis B virus (HBV) infection is endemic in China; perinatal transmission is the main source of
chronic HBV infection. Simultaneous administration of hepatitis B immune globulin (HBIG) and hepatitis B vaccine is
highly effective to prevent perinatal transmission of HBV; however, the effectiveness also depends on full adherence
to the recommended protocols in daily practice. In the present investigation, we aimed to identify gaps in
immunoprophylaxis of perinatal transmission of HBV between recommendations and routine practices in
Jiangsu Province, China.
Methods: Totally 626 children from 6 cities and 8 rural areas across Jiangsu Province, China, born from February
2003 to December 2004, were enrolled; 298 were born to mothers with positive hepatitis B surface antigen (HBsAg)
and 328 were born to HBsAg-negative mothers. Immunoprophylactic measures against hepatitis B were
retrospectively reviewed for about half of the children by checking medical records or vaccination cards and the
vaccine status was validated for most of children.
Results: Of 298 children born to HBV carrier mothers, 11 (3.7%) were HBsAg positive, while none of 328 children
born to non-carrier mothers was HBsAg positive (P < 0.01). The rates of anti-HBs≥ 10 mIU/ml in children of carrier
and non-carrier mothers were 69.5% and 69.2% respectively (P = 0.95). The hepatitis B vaccine coverage in two
groups was 100% and 99.4% respectively (P = 0.50), but 15.1% of HBV-exposed infants did not receive the timely
birth dose. Prenatal HBsAg screening was performed only in 156 (52.3%) of the carrier mothers. Consequently, only
112 (37.6%) of HBV-exposed infants received HBIG after birth. Furthermore, of the 11 HBV-infected children, only
one received both HBIG and hepatitis B vaccine timely, seven missed HBIG, two received delayed vaccination, and
one missed HBIG and received delayed vaccination.
Conclusions: There are substantial gaps in the prevention of perinatal HBV infection between the
recommendations and routine practices in China, which highlights the importance of full adherence to the
recommendations to eliminate perinatal HBV infection in the endemic regions.
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Background
Chronic hepatitis B virus (HBV) infection is a major
public health problem worldwide, particularly in Asia
and Africa, and Asian communities in low or high HBV
endemic areas [1,2]. Prevention of perinatal HBV infec-
tion from HBV carrier mothers to their infants is critical
to eliminate chronic hepatitis B since as high as 90% of
the neonatal infections will become chronically infected.
Simultaneous administration with one dose (0.5–1 ml,
100–200 IU) of hepatitis B immune globulin (HBIG)
within 12 hours after birth and three doses of hepatitis B
vaccine on a 0-, 1-, and 6-month schedule, which has
been adopted by many countries as well as China as the
recommended immunoprophylaxis for infants born to
HBV carrier mothers, is highly effective to prevent peri-
natal HBV infections [3-5]. Up to 2008, 177 countries
included the hepatitis B vaccine into their national infant
immunization programs [6]. The Chinese government
formally integrated hepatitis B vaccine into its Expanded
Program on Immunization (EPI) in 2002, and since then
all newborns in China may receive three doses of hepa-
titis B vaccine without charge [7,8].
The protective effect of a vaccine is not only dependent
on its quality, but also on full adherence to the recom-
mended protocols in daily practice. In developed coun-
tries, the vaccination schedule against hepatitis B has
been followed well in the routine practices and the pro-
tective efficiency was 90–100% in infants born to HBV
carrier mothers, as high as the protective rates achieved
in the clinical trials [9-12]. In developing countries like
China, where HBV infection is highly endemic, however,
the protective efficiency in daily practice has been less
studied. In the present study, we surveyed the adminis-
tration of hepatitis B vaccine and HBIG and measured
the serologic markers in infants born to HBV carrier
mothers based on the pregnant women population in
Jiangsu province, China, to determine whether there are
gaps in the immunoprophylaxis against perinatal HBV
transmission between national recommendations and the
routine practices after the integration of hepatitis B vac-
cine into the EPI of China.
Methods
Study design and subjects
During August 2002 to July 2004, serum samples from
19 904 pregnant women aged 20–42 years, at 15–20 weeks
of gestation, from 6 cities (urban) and 8 counties (rural
area) across Jiangsu Province, China, were collected in a
study on the provincial prevalence of birth defects [13].
The samples were stored at −30°C. These pregnant
women had been selected to represent the pregnant
women population in Jiangsu and all delivered their
infants in hospitals. Jiangsu Province is located in the east
of China, and is one of the six financially prosperous
provinces in China and has the densest population with
more than 76 million inhabitants. There are approxi-
mately 500 000 live births per year. Recently, we retro-
spectively measured the HBV serologic markers in the
6398 sera, which were randomly selected from above sam-
ples, and 429 (6.7%) were positive for hepatitis B surface
antigen (HBsAg) [14]. Of the 429 HBsAg positive sera, 10
were negative for antibody against hepatitis B core antigen
(anti-HBc) and either hepatitis B e antigen (HBeAg) or
anti-HBe. The positivity of HBsAg in these 10 samples
was validated by retesting with Architect HBsAg Reagents
(Abbott, North Chicago, USA) and by detection of HBV
DNA [14]; we speculated that these 10 women were in the
incubation period of HBV infection when the sera were
collected. Thus, we excluded these 10 women from the
study and planned to follow up the children of 419 HBsAg
positive women, of whom 125 (29.8%) were also positive
for HBeAg [14]. Because of the “one family one child pol-
icy” in China, the target population was the 419 children
born from February 2003 to December 2004 (Figure 1).
As control subjects, 453 children born to HBsAg negative
mothers in the same areas and same period of time were
randomly selected (Figure 1).
During October 2009 and March 2010, we invited
these mothers and their children to participate in the
present investigation as an “add-on” part of the project
on the provincial prevalence of birth defects [13]. Each
attending mother was asked to complete a questionnaire,
which included demographic data of the mother and her
child, screening for HBsAg during pregnancy, and use of
hepatitis B vaccine and HBIG in the child. Nearly half of
the HBsAg screening in pregnant women and the HBIG
administration in infants were validated by checking the
hospital discharge records. The use of hepatitis B vac-
cine was evidenced in 83.7% children by the vaccination
record cards. Furthermore, ~3 ml of blood was collected
from each child after obtaining the consent from the
child’s mother.
This study followed the ethical guidelines of the Dec-
laration of Helsinki, and was approved by the institu-
tional review boards of Nanjing Drum Tower Hospital
and Jiangsu Family Planning Institute. The pregnant
women consented to participate in the birth defect study
conducted from August 2002 to July 2004 [13] and their
serum samples were used in this study; the mothers con-
sented to be interviewed and consented to their chil-
dren's participation in this follow-up study.
Laboratory procedures
All serum samples were tested by commercial ELISA
kits for the presence of HBsAg, antibody to HBsAg
(anti-HBs), and anti-HBc. HBsAg was tested with an
ELISA kit (Huakang Biotech, Shenzhen, China), and
anti-HBs and anti-HBc were quantitatively tested with
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microparticle enzyme immunoassay (AxSYM AUSAB,
Abbott, North Chicago, USA). Quantitative levels of
anti-HBs were expressed in international units.
Definitions and statistical analysis
HBV infection was defined by the presence of HBsAg.
The presence of anti-HBc in the absence of HBsAg
represented resolved HBV infection. Timely vaccination
referred to receipt of the first dose of the vaccine within
24 hours after birth.
Data were analyzed using SPSS version 13 (SPSS
Inc., Chicago, USA). Statistical comparisons of continu-
ous variables between maternal HBsAg positive and
negative groups were analyzed by t-test. A χ2 test was
used to analyze and compare categorical data. A P value
of <0.05 was considered statistically significant.
Results
Effect of routine hepatitis B immunization on the
prevalence of HBV in infants of HBsAg positive mothers
Of the 419 invited mothers with positive HBsAg, 298
(71.1%) mothers and their children participated in the
study, while 328 (72.4%) of the 453 invited mothers who
were negative for HBsAg and their children attended the
investigation (Figure 1); the follow-up rates were com-
parable in these two groups (P > 0.05). Additionally, the
follow-up rate of children born to HBV carrier mothers
with positive HBeAg was also similar to that of children
of carrier mothers with negative HBeAg (72.0% vs.
70.7%, Figure 1). The demographic data, vaccination
coverage, status of HBV infection, and anti-HBs
responses in children are shown in Table 1. Almost all
infants in the both groups were vaccinated and the posi-
tive rates of anti-HBs were comparable. Of the children
born to HBsAg positive mothers, 11 (3.7%) were HBsAg
positive, demonstrating the HBV infection, and 16
(5.4%) were HBsAg negative but anti-HBc positive, indi-
cating past resolved infection, whereas none of the chil-
dren born to HBsAg negative mothers was infected with
HBV and only 0.9% had the resolved infection.
Administration of immunoprophylaxis in infants of HBsAg
positive mothers
Since recommended immunoprophylaxis against hepa-
titis B in infants born to HBsAg positive mothers
requires the timely use of hepatitis B vaccine and HBIG,
we particularly paid attention to collecting the data
about the preventive measures used in the routine prac-
tices (Table 2). Although prenatal HBsAg screening is
recommended for all pregnant women in China, the test
was not done in nearly a third of the pregnant women in
cities and more than half in rural areas. Consequently,
19904 pregnant women’s sera 
collected from 14 areas across 
Jiangsu, Aug. 2002-July 2004
6398 randomly selected







453 from same area
Actual follow-up, Oct. 
2009-March 2010
Children & mothers 
interviewed, sera
90 (72.0%) 208 (70.7%)
328 (72.4%)







Figure 1 Flow diagram of study subjects. HBsAg, hepatitis B surface antigen; a-HBs, antibody against HBsAg; a-HBc, antibody against hepatitis
B core antigen. HBeAg, hepatitis B e antigen.
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only 37.6% of the HBV-exposed infants received HBIG
after birth, and the use of HBIG in HBV-exposed infants
was less frequently in rural areas than in cities (55.7% vs.
32.0%, P <0.001). In other words, 62.4% of the infants
born to HBV carrier mothers were not administered
with HBIG in Jiangsu Province from February 2003
to December 2004. This was a substantial gap in the
prevention of HBV infection. Additionally, the first
dose of the vaccine was delayed in 15.1% of the HBV-
exposed infants.
Inadequate implementation of the immunoprophylaxis
responsible for most HBV infection in children
Of the 298 children born to HBV carrier mothers, 11
were infected with HBV and 16 experienced resolved
infections (Table 1). To clarify the factors responsible for
the infections, we analyzed the HBeAg status in their
mothers and the immunoprophylactic measures used in
these children. All 11 children infected with HBV and 12
of 16 children with the resolved infection were born to
HBeAg positive mothers. These results are in agreement
with the previous reports that children born to HBV car-
rier mothers with positive HBeAg are much more fre-
quently to be infected than those born to HBeAg
negative HBV carrier mothers [15,16]. On the other
hand, of the 11 children infected with HBV, only one
received timely administration of both HBIG and hepa-
titis B vaccine, and 10 others did not receive HBIG or
received delayed hepatitis B vaccine (Table 3). Of the 16
children with the resolved infections, 9 were not admi-
nistered with HBIG and one was given the first dose of
vaccine 40 days after birth (Table 3). The results demon-
strated that the infections in children born to HBV car-
rier mothers were mostly attributed to the inadequate
implementation of the immunoprophylaxis.
Discussion
In the present population-based study, we found that, al-
though most children of HBV carrier mothers were pro-
tected against chronic HBV infection after the
introduction of the universal immunization, there were
considerable gaps in the immunoprophylaxis of perinatal
HBV infection between the routine practices and na-
tional recommendations in China. Such gaps may also
exist in other developing countries since only 23.7% of
the 8–10-year-old children in East Java, Indonesia, were
anti-HBs positive after introduction of universal vaccin-
ation program [17] and the vaccine coverage in
remaining quilombo communities in Central Brazil is
suboptimal [18]. Therefore, the significance of full com-
pliance with the recommended procedures to prevent
perinatal HBV transmission should be emphasized in
China as well as other developing countries.
Prenatal HBsAg screening has been recommended in
all pregnant women in China since the late of 1980s,
however, the actual screening rate in the present investi-
gation was only 52.3%, far from the rates of 90–99% in
developed countries [19-22]. The gap is particularly sub-
stantial in the rural areas as only 46.9% of pregnant
women underwent the prenatal screening. Since all
investigated women had experienced prenatal examina-
tions and delivered their children in hospitals, we con-
sidered that the low HBsAg screening rate was largely
attributed to the health care providers’ unawareness of
the importance of the screening. We can imagine that
the adherence to preventive measures may be worse in
infants of mothers delivering at home in remote rural
areas of China. Thus, more intensive information about
Table 2 Immunoprophylaxis in infants of HBsAg positive mothers in Jiangsu, 2002–2004
Total n = 298 (%) Urban n= 70 (%) Rural n = 228 (%) P value
Prenatal HBsAg screening 156 (52.3) 49 (70.0) 107 (46.9) < 0.001
Use of HBIG for infants 112 (37.6) 39 (55.7) 73 (32.0) < 0.001
Use of HBV vaccine for infants 298 (100) 70 (100) 228 (100)
Timely birth dose 253 (84.9) 60 (85.7) 193 (84.6) 0.828
Fewer than three doses 21 (7.0) 3 (4.3) 18 (7.9) 0.357
Three doses but not on schedule 42 (14.1) 12 (17.1) 30 (13.2)
Three doses on time 235 (78.9) 54 (77.1) 181 (79.4)
Table 1 Demography, status of HBV infection and anti-









Age (year) 6.22 ± 0.82 6.25 ± 0.76 0.70
Male (%) 52.4 57.9 0.16
HBIG use (%) 112 (37.6) 0 –
Vaccination (%) 298 (100) 326 (99.4) 0.50
HBsAg+ (%) 11 (3.7) 0 < 0.01
HBsAg–/anti-HBc+ (%) 16 (5.5) 3 (0.9) 0.01
Anti-HBs > 10 mIU/ml (%) 207 (69.5) 227 (69.2) 0.95
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the importance of preventing mother-to-infant transmis-
sion of HBV should be provided to health care providers
as well as pregnant women to increase prenatal HBsAg
screening.
The administration of prophylactic measures against
hepatitis B in HBV-exposed infants was far from optimal
in China. Although all the infants received hepatitis B
vaccine, the birth dose was delayed in 15.1% of the new-
borns and three doses were not completed in 7% of
them. Furthermore, HBIG was used only in 37.6% of the
high risk infants. The untimely use of the birth dose
vaccine was apparently due to the oversight of the health
care providers since it is recommended that the birth
dose vaccine be given within 24 hours after birth. The
low usage of HBIG might be caused by several reasons,
first, unavailability of HBIG in some hospitals because
these hospitals do not have specific policies on prevent-
ing perinatal HBV infection; second, the lack of know-
ledge on the standard prophylaxis in the health care
providers; third, neglecting the use of HBIG by some
health care providers since the implementation of uni-
versal vaccination against hepatitis B, whatever the status
of the mother, might have been confusing for those not
specialized in HBV infection; and fourth, also most im-
portant, unknown HBsAg status in the pregnant women
before birth because of the low rate of prenatal HBsAg
screening. Unlike the recommendation in USA, in which
infants born to women with unknown HBsAg status are
administered with both HBIG and hepatitis B vaccine
[23], the policy in China is that only infants born to
known HBV carrier mothers receive passive-active
immunoprophylaxis.
Although only 3.7% of HBV-exposed infants in this in-
vestigation were infected with HBV, our findings indicate
that there is still a room to increase the protection con-
ferred by the vaccination against hepatitis B, because the
failure of the protection is largely due to the inappropri-
ate administration of the recommended prophylactic
procedures in the routine practices (Table 3). Addition-
ally, recent studies show that in developed countries,
98–100% of the HBV-exposed infants were protected
against the chronic infection after passive-active immu-
noprophylaxis had been strictly followed [9-12]. This
highlights the importance of the full adherence to the
standard immunoprophylaxis in the prevention of peri-
natal HBV infections.
There are some limitations in the present study. First,
the overall follow-up rate (71.1%) in HBV-exposed chil-
dren was not high. However, it is less likely that the
HBsAg positive rate in the children was biased due to
this reason, since a comparable follow-up rate (72%) in
children born to HBeAg positive carrier mothers, whose
infants are more prone to be infected, was achieved. Sec-
ond, the perinatal HBV infection in this study was exam-
ined at the age of 5–7 years, rather than at 12 months
old. However, spontaneous HBsAg loss in children peri-
natally infected is very low [24], and novel HBV infec-
tion in vaccinated children rarely occurs [25]. Thus, the
positive rate of HBsAg in children at ages of 5–7 years
whose mothers are infected with HBV may essentially
represent the perinatal infection. Third, the measures in
the routine practices investigated in this survey were
implemented during 2002–2004 and not all the data on
screening for HBsAg in pregnant women and adminis-
tration of HBIG in infants were validated by medical
Table 3 Immunoprophylaxis used in children with HBV
infection or resolved infection*
Child** HBIG (doses) Vaccination
Doses 1st 2nd (m) 3rd (m)
Children with positive HBsAg
A 2 3 24 h 1 6
B 2 3 2 m 5 unknown
C 2 3 1 m 2 7
D 0 3 7 d 1 6
E 0 3 24 h 1 6
F 0 3 24 h 1 6
G 0 3 24 h 1 6
H 0 3 24 h 1 6
I 0 3 24 h 1 6
J 0 3 24 h 1 6
K 0 3 24 h 1 6
Children with negative HBsAg and positive anti-HBc
a 2 3 24 h 1 6
b 2 3 24 h 1 6
c 2 3 24 h 1 6
d 1 3 24 h 1 6
e 1 3 24 h 1 6
f 1 3 24 h 1 6
g 1 3 24 h 1 6
h 0 3 24 h 1 6
i 0 3 24 h 1 6
j 0 3 24 h 1 6
k 0 3 24 h 1 6
l 0 3 40 d 2 5
m 0 2 24 h 1 –
n 0 3 24 h 1 6
o 0 3 24 h 1 6
p 0 3 24 h 1 6
*Mothers of children A–K and a–l were positive for both HBsAg and HBeAg,
and mothers of children m–p were positive for HBsAg and negative for
HBeAg.
**Children a–j and l–n were also positive for anti-HBs, and children k, o, and p
were negative for anti-HBs.
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records; the current status of services for infants of HBV
carrier mothers could be improved. However, a recent
preliminary survey in the prevention of perinatal HBV
transmission among obstetric and gynecological medical
staffs in China showed that there is insufficient training
in the application of immunoprophylaxis, particularly in
rural areas (unpublished data), suggesting there is a big
room to improve the immunoprophylaxis against hepa-
titis B. On the other hand, there are two strengths in
this study. One is that the study subjects were from 14
areas across Jiangsu; the data should be superior to those
from a single center study. The other is that we con-
ducted this study as the third party in a more objective
manner.
Although the results in this study were derived from a
province in China, we consider that the identified gaps
also exist in most areas of China as Jiangsu is one of the
six financially prosperous regions among the 31 pro-
vinces in Mainland China. We also consider that the
data of the present study may basically reflect the sce-
nario in some developing countries like China. Thus, a
national organization dedicated to educating health care
providers in delivery units and delivery hospitals about
the knowledge of preventing perinatal HBV infection
will be critical for filling the gaps.
Conclusions
Despite the availability of effective immunoprophylaxis
in the prevention of perinatal transmission of HBV for
more than 20 years, there are substantial gaps between
the recommendations and routine practices in China,
which highlights the importance of full adherence to the
recommendations to eliminate perinatal HBV infections
in the endemic regions.
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